vorinostat has been researched along with Seizures in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Previous work demonstrated the convulsive and widespread neuropathological effects of soman, an organophosphorus compound that causes SE and severe recurrent seizures as a result of exposure." | 7.78 | Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. ( Addis, M; Bailey, K; Chanda, S; de Araujo Furtado, M; Lumley, LA; Moffett, M; Pak, T; Robertson, BD; Rossetti, F; Shields, M; Yourick, DL, 2012) |
| "Sprague-Dawley rats with kainic acid (KA)-induced seizures were treated with SAHA." | 3.83 | Histone deacetylase inhibitor SAHA attenuates post-seizure hippocampal microglia TLR4/MYD88 signaling and inhibits TLR4 gene expression via histone acetylation. ( Hu, QP; Mao, DA, 2016) |
| " Previous work demonstrated the convulsive and widespread neuropathological effects of soman, an organophosphorus compound that causes SE and severe recurrent seizures as a result of exposure." | 3.78 | Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. ( Addis, M; Bailey, K; Chanda, S; de Araujo Furtado, M; Lumley, LA; Moffett, M; Pak, T; Robertson, BD; Rossetti, F; Shields, M; Yourick, DL, 2012) |
| "Despite the development of newer anti-seizure medications over the past 50 years, 30-40% of patients with epilepsy remain refractory to treatment." | 1.48 | A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target. ( de la Hoz, CL; Gavrilovici, C; Ibhazehiebo, K; Kaushik, G; Kim, DY; Kurrasch, DM; Ma, SC; Meza Santoscoy, PL; Nath, N; Rehak, R; Rho, JM; Scott, L, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibhazehiebo, K | 1 |
| Gavrilovici, C | 1 |
| de la Hoz, CL | 1 |
| Ma, SC | 1 |
| Rehak, R | 1 |
| Kaushik, G | 1 |
| Meza Santoscoy, PL | 1 |
| Scott, L | 1 |
| Nath, N | 1 |
| Kim, DY | 1 |
| Rho, JM | 1 |
| Kurrasch, DM | 1 |
| Hu, QP | 1 |
| Mao, DA | 1 |
| Rossetti, F | 1 |
| de Araujo Furtado, M | 1 |
| Pak, T | 1 |
| Bailey, K | 1 |
| Shields, M | 1 |
| Chanda, S | 1 |
| Addis, M | 1 |
| Robertson, BD | 1 |
| Moffett, M | 1 |
| Lumley, LA | 1 |
| Yourick, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Clinical Trial Testing the Safety and Efficacy of Voronistat in Pediatric Patients With Drug Resistant Epilepsy[NCT03894826] | Phase 2 | 12 participants (Anticipated) | Interventional | 2018-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for vorinostat and Seizures
| Article | Year |
|---|---|
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
Topics: Animals; Animals, Genetically Modified; Anticonvulsants; Disease Models, Animal; Drug Delivery Syste | 2018 |
Histone deacetylase inhibitor SAHA attenuates post-seizure hippocampal microglia TLR4/MYD88 signaling and inhibits TLR4 gene expression via histone acetylation.
Topics: Acetylation; Animals; Anticonvulsants; Apoptosis; CA1 Region, Hippocampal; Disease Models, Animal; D | 2016 |
Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure.
Topics: Animals; Anticonvulsants; Brain; Brain Mapping; Brain Waves; Chemical Warfare Agents; Cytoprotection | 2012 |